Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during The American Society of Hematology (ASH) annual meeting, December 9-12 in San Diego, CA. The event will feature plenary, oral abstract, education, and special sessions representing the most cutting-edge science in hematology.
MSK experts will be available to comment on their high-profile research on topics such as Follicular Lymphoma, Lymphoid Leukemias, Myelofibrosis, and more, including:
- Salima Benbarche, PhD, will present findings that demonstrate the power of synthetic intronic splicing assays for the discovery of novel factors and druggable proteins required by leukemia-associated mutations in the RNA splicing factors during the meeting’s plenary session on Sunday, December 10th at 2:00 p.m. PT.
- Lorenzo Falchi, MD, will present a phase II study that tested the bispecific antibody mosunetuzumab, a chemo-free immunotherapy, to treat patients with newly diagnosed follicular lymphoma. Mosunetuzumab, which enables the patient’s own immune cells to kill the lymphoma cells, showed very promising early results – the presentation will occur on Sunday, December 10th at 5:15 p.m. PT.
- Steven M. Horwitz, MD, will present the phase 2 results of a novel therapy, valemetostat, for relapsed Peripheral T-cell lymphoma (PTCL), which is an aggressive non-Hodgkin lymphoma (NHL), with limited available treatment options for patients with relapsed or refractory disease – the presentation will take place on Saturday, December 9th at 4:15 p.m. PT.
- Raajit K. Rampal, MD, PhD, will present a phase III study on Myelofibrosis, which seeks to compare ruxolitinib, the main standard of care treatments for this disease, to the combination of ruxolitinib and Pelabresib (a novel BET inhibitor) on Sunday, December 10th at 5:15 p.m. PT.
ASH 2023 Honorific Award Recipient
Earlier this year, ASH announced that Omar Abdel-Wahab, MD, will be recognized with the William Dameshek Prize, which is awarded each year to an individual who has made outstanding contributions in hematology, at the annual meeting. Dr. Abdel-Wahab is being honored for his research on the genetic mutations that drive blood cancers, which currently focuses on the recurrent RNA splicing mutations that lead to the development of myelodysplastic syndromes and leukemia. His discoveries have paved the way for the development of multiple drugs targeting RNA splicing activity, which are now in the early phases of clinical development. Additionally, his research has played a pivotal role in securing U.S. Food and Drug Administration (FDA) approval of the first targeted therapies for patients with systemic histiocytic neoplasms.
CONTACT
John Connolly
[email protected]